Regeneron Pharmaceuticals (REGN) debt: $2B
Regeneron Pharmaceuticals had $2B of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $2B a year earlier.
From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page
Regeneron Pharmaceuticals debt by year
#647 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $2B | +0% |
| Dec 31, 2024 | $2B | +0% |
| Dec 31, 2023 | $2B | +0% |
| Dec 31, 2022 | $2B | +0% |
| Dec 31, 2021 | $2B | – |
Debt of similar companies
Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Elanco Animal Health | $3.8B | Dec 31, 2025 |
| PERRIGO | $3.6B | Dec 31, 2025 |
| Amneal Pharmaceuticals | $2.6B | Dec 31, 2025 |
| BridgeBio Pharma | $2B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $2B | Dec 31, 2025 |
| Ionis Pharmaceuticals | $1.8B | Dec 31, 2025 |
| Prestige Consumer Healthcare | $1B | Dec 31, 2025 |
Questions and answers
What is Regeneron Pharmaceuticals's debt?
Regeneron Pharmaceuticals had $2B of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $2B a year earlier.
Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology